<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852459</url>
  </required_header>
  <id_info>
    <org_study_id>AP-007</org_study_id>
    <nct_id>NCT03852459</nct_id>
  </id_info>
  <brief_title>Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS</brief_title>
  <official_title>A Randomized, Double-Blind,Vehicle-Controlled Study to Determine the Efficacy and Safety of AP0302 in the Treatment of Delayed Onset Muscle Soreness (DOMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aponia Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aponia Laboratories, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel
      5%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of
      S-Ibuprofen Topical Gel 5% in reducing pain/soreness associated with delayed onset muscle
      soreness (DOMS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">April 11, 2019</completion_date>
  <primary_completion_date type="Actual">April 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>active gel and matching vehicle control gel</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of time weighted pain intensity (SPID) differences from baseline with movement over 24 hours post time zero</measure>
    <time_frame>24 hours</time_frame>
    <description>SPID move 0-24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of time weighted differences from baseline in muscle stiffness (SSID) with movement over the intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-48, and 0-48 hours post time zero</measure>
    <time_frame>From 0 to 48 hours</time_frame>
    <description>SSID move (various intervals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief with movement (TOTPAR) 0-6 hours post time zero</measure>
    <time_frame>0-6 hours</time_frame>
    <description>TOTPAR move 0-6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject global assessment of study medication assessed at approximately 48 hours post time zero</measure>
    <time_frame>48 hours post time zero</time_frame>
    <description>Self-reported global assessment of study medication at the end of the study (reported categorically as poor, fair, good, very good, excellent)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-Ibuprofen Topical Gel 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Ibuprofen</intervention_name>
    <description>Topical Gel 5%</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle Gel</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of pain/soreness after exercise

          -  BMI between 18-30

          -  negative drug, alcohol, pregnancy screens

          -  other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  upper extremity workout in last 3 months

          -  job or hobby requiring heavy lifting

          -  history of muscle disorders

          -  allergy or intolerance to NSAID or study drug

          -  history of recent pain medication use

          -  other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Bertoch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JBR Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>May 4, 2019</last_update_submitted>
  <last_update_submitted_qc>May 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

